The goal of this clinical trial is to investigate the role of colchicine in reducing the rate of myocardial reperfusion injury in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. The main questions it aims to answer are: * Does colchicine reduce the rate of myocardial reperfusion injury ? * Does colchicine reduce the concentration of markers of myocardial reperfusion injury (NLRP3, ASC, caspase, and troponin) ? Participants will * Be grouped into intervention group and control group blindly. Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days. Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days. * Undergo peripheral blood vein examination before primary percutaneous coronary intervention, after primary percutaneous coronary intervention, 24 hour after primary percutaneous coronary intervention, and 48 hour after primary percutaneous coronary intervention. Researchers will compare intervention group and control group to see if colchicine reduces the rate of myocardial reperfusion injury and reduces the concentration of markers of myocardial reperfusion injury (NLRP3, ASC, caspase, and troponin) in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
Fakultas Kedokteran Universitas Indonesia
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
The Rate of Myocardial Reperfusion Injury
The rate of hypotension, acute heart failure, arrhythmias, persistent chest pain, or microvascular obstruction up to 3 days after primary percutaneous coronary intervention after primary percutaneous coronary intervention
Time frame: Up to 3 days after primary percutaneous coronary intervention
Activation of NLRP3 in peripheral blood vein measured in counts
Activation of NLRP3 in peripheral blood vein 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention measured in counts
Time frame: 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention
Concentration of ASC in peripheral blood vein in ng/ml
Concentration of ASC in peripheral blood vein 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention in ng/ml
Time frame: 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention
Concentration of caspase in peripheral blood vein in pg/ml
Concentration of caspase in peripheral blood vein 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention in pg/ml
Time frame: 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention
Concentration of troponin in peripheral blood vein in ng/L
Concentration of troponin in peripheral blood vein 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention in ng/L
Time frame: 30 minutes before, 30 minutes after, 24 hours after, and 48 hours after primary percutaneous coronary intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.